FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia

Journal of Clinical Investigation

Volumn 117, Issue 9, 2007, Pages 2408-2421

  Neviani, Paolo ^a   Santhanam, Ramasamy ^a   Oaks, Joshua J ^a   Eiring, Anna M ^a   Notari, Mario ^a   Blaser, Bradley W ^a   Liu, Shujun ^a   Trotta, Rossana ^a   Muthusamy, Natarajan ^a   Gambacorti Passerini, Carlo ^b   Druker, Brian J ^c   Cortes, Jorge ^d   Marcucci, Guido ^a,e   Chen, Ching Shih ^a,e   Verrills, Nicole M ^f   Roy, Denis C ^g   Caligiuri, Michael A ^a,e   Bloomfield, Clara D ^e   Byrd, John C ^a,e   Perrotti, Danilo ^a,e  

^a OHIO STATE UNIVERSITY   (United States)

^b SAN GERARDO HOSPITAL   (Italy)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF NEWCASTLE   (Australia)

^g UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD19 ANTIGEN; CD34 ANTIGEN; DASATINIB; FINGOLIMOD; IMATINIB; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN P190;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLONOGENESIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL;

ANIMALS; BLAST CRISIS; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MICE; MOLECULAR STRUCTURE; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHORYLATION; PIPERAZINES; PROPYLENE GLYCOLS; PYRIMIDINES; SIGNAL TRANSDUCTION; SPHINGOSINE; THIAZOLES; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 34648832173     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI31095     Document Type: Article

References (78)

1. Rowley, J.D. 1973. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 243:290-293.
2. Westbrook, C.A., et al. 1992. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood. 80:2983-2990.
3. Melo, J.V. 1996. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 88:2375-2384.
4. Li, S., Ilaria, R.L., Jr., Million, R.P., Daley, G.Q., and Van Etten, R.A. 1999. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J. Exp. Med. 189:1399-1412.
5. Daley, G.Q., Van Etten, R.A., and Baltimore, D. 1990. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 247:824-830.
6. Bedi, A., Zehnbauer, B.A., Barber, J.P., Sharkis, S.J., and Jones, R.J. 1994. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood. 83:2038-2044.
7. Savage, D.G., Szydlo, R.M., and Goldman, J.M. 1997. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br. J. Haematol. 96:111-116.
8. Calabretta, B., and Perrotti, D. 2004. The biology of CML blast crisis. Blood. 103:4010-4022.
9. Castor, A., et al. 2005. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat. Med. 11:630-637.
10. Cobaleda, C., et al. 2000. A primitive hematopoietic cell is the target for the leukemic transformation in human Philadelphia-positive acute lymphoblastic leukemia. Blood. 95:1007-1013.
11. Marley, S.B., and Gordon, M.Y. 2005. Chronic myeloid leukaemia: stem cell derived but progenitor cell driven. Clin. Sci. (Lond.). 109:13-25.
12. Voncken, J.W., et al. 1995. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice. Blood. 86:4603-4611.
13. Faderl, S., Jeha, S., and Kantarjian, H.M. 2003. The biology and therapy of adult acute lymphoblastic leukemia. Cancer. 98:1337-1354.
14. Melo, J.V., and Deininger, M.W. 2004. Biology of chronic myelogenous leukemia - signaling pathways of initiation and transformation. Hematol. Oncol. Clin. North Am. 18:545-568, vii-viii.
15. Druker, B.J., et al. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2:561-566.
16. Deininger, M., Buchdunger, E., and Druker, B.J. 2005. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 105:2640-2653.
17. Roy, L., et al. 2006. Survival advantage from imatinib compared to the combination interferon alpha plus cytarabine in chronic phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood. 108:1478-1484.
18. Cohen, M.H., Johnson, J.R., and Pazdur, R. 2005. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin. Cancer Res. 11:12-19.
19. Druker, B.J., et al. 2001. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344:1038-1042.
20. Ottmann, O.G., et al. 2002. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 100:1965-1971.
21. Shah, N.P., and Sawyers, C.L. 2003. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene. 22:7389-7395.
22. Kantarjian, H., et al. 2006. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354:2542-2551.
23. Talpaz, M., et al. 2006. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354:2531-2541.
24. O'Hare, T., et al. 2005. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 65:4500-4505.
25. Deininger, M.W.N., et al. 2005. Comparison of imatinib, AMN107 and dasatinib in an accelerated cellbased mutagenesis screen [abstract]. Blood (ASH Annual Meeting Abstracts). 106:691.
26. Neviani, P., et al. 2005. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell. 8:355-368.
27. Matsuoka, Y., Nagahara, Y., Ikekita, M., and Shinomiya, T. 2003. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br. J. Pharmacol. 138:1303-1312.
28. Brinkmann, V. 2004. FTY720: mechanism of action and potential benefit in organ transplantation. Yonsei Med. J. 45:991-997.
29. Kahan, B.D. 2004. FTY720: from bench to bedside. Transplant Proc. 36:531S-543S.
30. Kovarik, J.M., et al. 2004. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J. Clin. Pharmacol. 44:532-537.
31. Chiba, K. 2005. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol. Ther. 108:308-319.
32. Dumont, F.J. 2005. Fingolimod. Mitsubishi Pharma/Novartis. IDrugs. 8:236-253.
33. Virley, D.J. 2005. Developing therapeutics for the treatment of multiple sclerosis. NeuroRx. 2:638-649.
34. Budde, K., et al. 2002. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J. Am. Soc. Nephrol. 13:1073-1083.
35. Skerjanec, A., et al. 2005. FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship. J. Clin. Pharmacol. 45:1268-1278.
36. Brinkmann, V., et al. 2002. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 277:21453-21457.
37. Li, M., Makkinje, A., and Damuni, Z. 1996. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J. Biol. Chem. 271:11059-11062.
38. Janssens, V., and Goris, J. 2001. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem. J. 353:417-439.
39. Sontag, E. 2001. Protein phosphatase 2A: the Trojan Horse of cellular signaling. Cell Signal. 13:7-16.
40. Yang, S.I., et al. 1991. Control of protein phosphatase 2A by simian virus 40 small-t antigen. Mol. Cell. Biol. 11:1988-1995.
41. Notari, M., et al. 2006. A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood. 107:2507- 2516.
42. Gomez, N., and Cohen, P. 1991. Dissection of the protein kinase cascade by which nerve growth factor activates MAP kinases. Nature. 353:170-173.
43. Sato, S., Fujita, N., and Tsuruo, T. 2000. Modulation of Akt kinase activity by binding to Hsp90. Proc. Natl. Acad. Sci. U. S. A. 97:10832-10837.
44. Yokoyama, N., Reich, N.C., and Miller, W.T. 2001. Involvement of protein phosphatase 2A in the interleukin-3-stimulated Jak2-Stat5 signaling pathway. J. Interferon Cytokine Res. 21:369-378.
45. Saydam, G., et al. 2003. Involvement of protein phosphatase 2A in interferon-alpha-2b-induced apoptosis in K562 human chronic myelogenous leukaemia cells. Leuk. Res. 27:709-717.
46. Windh, R.T., et al. 1999. Differential coupling of the sphingosine 1-phosphate receptors Edg-1, Edg-3, and H218/Edg-5 to the G(i), G(q), and G(12) families of heterotrimeric G proteins. J. Biol. Chem. 274:27351-27358.
47. Yopp, A.C., et al. 2005. Sphingosine 1-phosphate receptors regulate chemokine-driven transendothelial migration of lymph node but not splenic T cells. J. Immunol. 175:2913-2924.
48. Butler, J., Lana, D., Round, O., and LaMontagne, K. 2004. Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cells. Prostaglandins Other Lipid Mediat. 73:29-45.
49. Tolle, M., et al. 2005. Immunomodulator FTY720 induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3. Circ. Res. 96:913-920.
50. Jendiroba, D.B., Klostergaard, J., Keyhani, A., Pagliaro, L., and Freireich, E.J. 2002. Effective cytotoxicity against human leukemias and chemotherapy-resistant leukemia cell lines by N-Ndimethylsphingosine. Leuk. Res. 26:301-310.
51. French, K.J., et al. 2003. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 63:5962-5969.
52. Uckun, F.M., et al. 1991. Interleukin 7 receptor ligation stimulates tyrosine phosphorylation, inositol phospholipid turnover, and clonal proliferation of human B-cell precursors. Proc. Natl. Acad. Sci. U. S. A. 88:3589-3593.
53. Azuma, H., et al. 2003. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J. Urol. 169:2372-2377.
54. Azuma, H., et al. 2002. Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res. 62:1410-1419.
55. Lee, T.K., et al. 2005. FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma. Clin. Cancer Res. 11:8458-8466.
56. Sonoda, Y., et al. 2001. FTY720, a novel immunosuppressive agent, induces apoptosis in human glioma cells. Biochem. Biophys. Res. Commun. 281:282-288.
57. Yasui, H., et al. 2005. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res. 65:7478-7484.
58. Ho, J.W., et al. 2005. Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma. Mol. Cancer Ther. 4:1430-1438.
59. Xin, C., Ren, S., Pfeilschifter, J., and Huwiler, A. 2004. Heterologous desensitization of the sphingosine-1-phosphate receptors by purinoceptor activation in renal mesangial cells. Br. J. Pharmacol. 143:581-589.
60. Cortez, D., Reuther, G., and Pendergast, A.M. 1997. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene. 15:2333-2342.
61. Zemann, B., et al. 2006. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood. 107:1454-1458.
62. Ogretmen, B., and Hannun, Y.A. 2004. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat. Rev. Cancer. 4:604-616.
63. Suzuki, E., Handa, K., Toledo, M.S., and Hakomori, S. 2004. Sphingosine-dependent apoptosis: a unified concept based on multiple mechanisms operating in concert. Proc. Natl. Acad. Sci. U. S. A. 101:14788-14793.
64. Dobrowsky, R.T., Kamibayashi, C., Mumby, M.C., and Hannun, Y.A. 1993. Ceramide activates heterotrimeric protein phosphatase 2A. J. Biol. Chem. 268:15523-15530.
65. Wang, E., Norred, W.P., Bacon, C.W., Riley, R.T., and Merrill, A.H., Jr. 1991. Inhibition of sphingolipid biosynthesis by fumonisins. Implications for diseases associated with Fusarium moniliforme. J. Biol. Chem. 266:14486-14490.
66. Alvarado-Kristensson, M., and Andersson, T. 2005. Protein phosphatase 2A regulates apoptosis in neutrophils by dephosphorylating both p38 MAPK and its substrate caspase 3. J. Biol. Chem. 280:6238-6244.
67. Moon, E.Y., and Lerner, A. 2003. PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A. Blood. 101:4122-4130.
68. Van Hoof, C., and Goris, J. 2003. Phosphatases in apoptosis: to be or not to be, PP2A is in the heart of the question. Biochim. Biophys. Acta. 1640:97-104.
69. Brinkmann, V., Cyster, J.G., and Hla, T. 2004. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am. J. Transplant. 4:1019-1025.
70. Lee, T.K., et al. 2004. FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation. Carcinogenesis. 25:2397-2405.
71. Kim, Y.M., Sachs, T., Asavaroengchai, W., Bronson, R., and Sykes, M. 2003. Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J. Clin. Invest. 111:659-669. doi:10.1172/JCI200316950.
72. Kahan, B.D. 1998. FTY720: a new immunosuppressive agent with novel mechanism(s) of action. Transplant Proc. 30:2210-2213.
73. Perrotti, D., et al. 2002. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat. Genet. 30:48-58.
74. Seidel, G., Laurich, D., and Furstner, A. 2004. Iron-catalyzed cross-coupling reactions. A scalable synthesis of the immunosuppressive agent FTY720. J. Org. Chem. 69:3950-3952.
75. Boehm, J.S., Hession, M.T., Bulmer, S.E., and Hahn, W.C. 2005. Transformation of human and murine fibroblasts without viral oncoproteins. Mol. Cell. Biol. 25:6464-6474.
76. Cross, N.C., et al. 1993. Competitive polymerase chain reaction to estimate the number of BCRABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood. 82:1929-1936.
77. Cross, N.C., Melo, J.V., Feng, L., and Goldman, J.M. 1994. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia. 8:186-189.
78. Hattori, M., et al. 1995. Detection of major and minor bcr/abl fusion gene transcripts in a patient with acute undifferentiated leukemia secondary to treatment with an alkylating agent. Leuk. Res. 19:389-396.